| Diffuse Large B-Cell Lymphoma
Polivy vs Xpovio
Side-by-side clinical, coverage, and cost comparison for diffuse large b-cell lymphoma.Deep comparison between: Polivy vs Xpovio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXpovio has a higher rate of injection site reactions vs Polivy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xpovio but not Polivy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Polivy
Xpovio
At A Glance
IV infusion
Every 21 days
CD79b-directed antibody-drug conjugate
Oral
Once or twice weekly
XPO1 inhibitor
Indications
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Multiple Myeloma
- Diffuse Large B-Cell Lymphoma
Dosing
Diffuse Large B-Cell Lymphoma (previously untreated), HGBL 1.8 mg/kg IV infusion every 21 days for 6 cycles in combination with rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP); administer initial dose over 90 minutes, subsequent doses may be given over 30 minutes if tolerated.
Diffuse Large B-Cell Lymphoma (relapsed or refractory) 1.8 mg/kg IV infusion every 21 days for 6 cycles in combination with bendamustine and a rituximab product; administer initial dose over 90 minutes, subsequent doses may be given over 30 minutes if tolerated.
Multiple Myeloma (with Bortezomib and Dexamethasone) 100 mg orally once weekly on Day 1 of each week in combination with bortezomib 1.3 mg/m2 SC once weekly and dexamethasone 20 mg orally twice weekly on Days 1 and 2.
Multiple Myeloma (with Dexamethasone) 80 mg orally on Days 1 and 3 of each week in combination with dexamethasone 20 mg orally on Days 1 and 3 of each week.
Diffuse Large B-Cell Lymphoma 60 mg orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Peripheral neuropathy, neutropenia, thrombocytopenia, anemia, fatigue, diarrhea, nausea, constipation, alopecia, mucositis, pyrexia, decreased appetite
Serious Peripheral neuropathy, infusion-related reactions, myelosuppression, serious and opportunistic infections, progressive multifocal leukoencephalopathy, tumor lysis syndrome, hepatotoxicity, infusion site extravasation injury
Most common (>=20%) Fatigue, nausea, thrombocytopenia, decreased appetite, diarrhea, vomiting, weight decreased, anemia, peripheral neuropathy, upper respiratory tract infection, hyponatremia, cataract
Serious Thrombocytopenia, neutropenia, gastrointestinal toxicity (nausea, vomiting, diarrhea, weight loss), hyponatremia, serious infection (including pneumonia and sepsis), neurological toxicity, cataract
Pharmacology
Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate; the monoclonal antibody binds CD79b on B cells, is internalized, and releases MMAE intracellularly via lysosomal protease cleavage, where MMAE binds microtubules to inhibit cell division and induce apoptosis in dividing B cells.
Selinexor reversibly inhibits exportin 1 (XPO1), blocking nuclear export of tumor suppressor proteins and oncogenic mRNAs, causing nuclear accumulation of tumor suppressors, downregulation of oncoproteins such as c-myc and cyclin D1, cell cycle arrest, and apoptosis of cancer cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Polivy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Xpovio
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Polivy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xpovio
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Polivy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Xpovio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/momo
Xpovio Co-Pay CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PolivyView full Polivy profile
XpovioView full Xpovio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.